Alpha-1 antitrypsin deficiency (AATD): improving treatment and reducing barriers to care
Posted by...Bernard Sklar, MD.
Free Pulmonology and Genetics CME Credit Hours...1.0.
CME Credits Awarded by....ScientiaCME.
Instruction Type....Slide-Video Lectures.
Target Audiences....Pulmonologists and primary care physicians; physician assistants, nurse practitioners, nurses, and pharmacists who practice in pulmonology and internal medicine; and any other healthcare professionals with an interest in or who clinically encounter patients with AATD.
Educational material last updated...June 26, 2017.
Expiration of CME credit...June 26, 2019.
Topics covered in Alpha-1 antitrypsin deficiency (AATD): improving treatment and reducing barriers to care
Epidemiology, clinical features, presentation, pathophysiology, and disease progression, patient population identification among healthcare professionals of different specialties, diagnostic tests, genetic testing and patient cases.
After completing Alpha-1 antitrypsin deficiency (AATD): improving treatment and reducing barriers to care
, you will be able to:
• Describe the pathophysiology of AATD and how it impacts treatment of the disorder
• Assess the clinical significance of AATD laboratory results and apply them to patient cases
• Describe the clinical presentation of patients with A1ATD and, given a patient case, formulate a treatment plan
• Recall barriers to care for AATD and its clinical management in current practice